The stock of Roka Bioscience Inc (NASDAQ:ROKA) reached all time low today, Oct, 31 and still has $3.92 target or 14.00% below today’s $4.56 share price. This indicates more downside for the $8.31M company. This technical setup was reported by Barchart.com. If the $3.92 PT is reached, the company will be worth $1.16M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 17,194 shares traded hands. Roka Bioscience Inc (NASDAQ:ROKA) has declined 31.11% since March 29, 2016 and is downtrending. It has underperformed by 34.59% the S&P500.
Analysts await Roka Bioscience Inc (NASDAQ:ROKA) to report earnings on November, 9.
Roka Bioscience Inc (NASDAQ:ROKA) Ratings Coverage
Out of 3 analysts covering Roka Bioscience (NASDAQ:ROKA), 0 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 0 are positive. Roka Bioscience has been the topic of 7 analyst reports since August 14, 2015 according to StockzIntelligence Inc. Leerink Swann downgraded the stock to “Market Perform” rating in Monday, March 7 report. The company was upgraded on Tuesday, September 8 by Zacks. The firm has “Outperform” rating by Leerink Swann given on Friday, August 14. The rating was downgraded by Zacks to “Hold” on Tuesday, August 25.
According to Zacks Investment Research, “Roka Bioscience, Inc. is a molecular diagnostics company. It is focused on developing and commercializing advanced testing solutions for the food safety testing market. Roka provides Atlas instrument, a fully automated molecular diagnostic testing instrument to reduce labor costs and operator error in high-volume foodborne pathogen testing laboratories. The company also offers atlas detection assays that include tests for Salmonella, Listeria, E. coli O157:H7, Shiga toxin-producing E. coli, and Listeria monocytogenes, as well as related consumable supplies. Roka Bioscience, Inc. is headquartered in Warren, New Jersey.”
Insitutional Activity: The institutional sentiment increased to 0.5 in Q2 2016. Its up 0.23, from 0.27 in 2016Q1. The ratio improved, as 4 funds sold all Roka Bioscience Inc shares owned while 2 reduced positions. 1 funds bought stakes while 2 increased positions. They now own 11.75 million shares or 4.44% less from 12.30 million shares in 2016Q1.
Geode Cap Management Limited Company holds 0% of its portfolio in Roka Bioscience Inc (NASDAQ:ROKA) for 20,739 shares. Renaissance Ltd Llc accumulated 55,400 shares or 0% of the stock. Tudor Investment Et Al accumulated 32,545 shares or 0% of the stock. Craig A accumulated 1.60M shares or 1.8% of the stock. Manufacturers Life Insur The has 746 shares for 0% of their US portfolio. Cannell Peter B & Incorporated holds 0% or 58,098 shares in its portfolio. Weiss Multi, a Alabama-based fund reported 54,675 shares. Nea Commerce Ltd Liability Company has invested 0.1% of its portfolio in Roka Bioscience Inc (NASDAQ:ROKA). Bridgeway Management Inc, a Texas-based fund reported 207,500 shares. The New York-based Orbimed Ltd Limited Liability Company has invested 0.02% in Roka Bioscience Inc (NASDAQ:ROKA). Wells Fargo & Com Mn last reported 100 shares in the company. Vanguard holds 22,486 shares or 0% of its portfolio. Savings Bank Of America Corporation De reported 4,018 shares or 0% of all its holdings. The Ontario – Canada-based Royal National Bank & Trust Of Canada has invested 0% in Roka Bioscience Inc (NASDAQ:ROKA). Birchview Cap Limited Partnership holds 0.1% or 252,307 shares in its portfolio.
More notable recent Roka Bioscience Inc (NASDAQ:ROKA) news were published by: Prnewswire.com which released: “Roka Bioscience, Inc. Announces One-For-Ten Reverse Stock Split” on October 11, 2016, also Prnewswire.com with their article: “Roka Bioscience, Inc. Prices Private Placement of Preferred Stock and Warrants” published on September 16, 2016, Marketwatch.com published: “Roka Bioscience upgraded to outperform from market perform at Leerink Partners” on July 17, 2014. More interesting news about Roka Bioscience Inc (NASDAQ:ROKA) were released by: Prnewswire.com and their article: “Roka Bioscience, Inc. Completes Private Placement of Preferred Stock and Warrants” published on September 22, 2016 as well as Prnewswire.com‘s news article titled: “Roka Bioscience Reports Second Quarter 2016 Financial Results” with publication date: August 05, 2016.
ROKA Company Profile
Roka Bioscience, Inc., incorporated on September 3, 2009, is a molecular diagnostics company. The Firm is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Firm offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture assays, immunochemical assays and molecular assays. The Firm sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company’s Atlas instrument is an automated molecular diagnostic testing instrument designed to reduce labor costs and operator error in foodborne pathogen testing laboratories. The Atlas instrument is a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.